Chemomab Therapeutics Ltd. (CMMB): Total Assets
$13.81M
As of 2025-12-31
-31.5%
3-year compound annual growth
+2.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.81M | -18.6% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $16.96M | -23.4% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $22.15M | -48.6% | 2025-04-04, Balance as of period end |
| 2022-12-31 | $43.06M | -33.1% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $64.35M | +415.8% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $12.48M | -36.8% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $19.75M | +54.8% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $12.76M | n/a | 2020-03-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $13.81M | -18.6% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $13.97M | -22.6% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $14.04M | +50.6% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $13.59M | -31.3% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $14.04M | -6.7% |
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | $13.53M | +254.8% |
| Biovie Inc. (BIVI) | 2026-06-30 | $14.25M | -33.9% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $12.96M | +254.9% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $12.87M | +43.1% |
Compare CMMB, CYDY, ACTU, CALC side by side · Screen every company in Pharmaceutical Preparations ↗